Artificial intelligence and digital pathology: a look to the future

In recent years, life sciences organisations have digitised every possible aspect of their laboratories in the hopes of speeding drug discovery and ensuring high-quality, efficient laboratory operations. While many of these companies are at the forefront of adopting digital pathology, the majority of the millions of images and massive volumes of associated data that they have generated through whole-slide imaging remains siloed and, in turn, dissociated from broader research and development (R&D) efforts.

As the digitisation of pathology in R&D becomes a ubiquitous feature, these life sciences organisations are looking to build scalable technology ecosystems that functionalise their digital pathology data. Doing so will entail architecting and maintaining a robust technology platform that provides the capabilities, interface and technical back-end to enable researchers and pathologists to streamline workflows, collaborate with global peers, and enjoy broadened access to pathology data. All of this is much more easily said than done.

This is why Proscia continues to expand its Concentriq digital pathology platform for life sciences to meet the needs of organisations that are ready for the next generation of enterprise-class software. As Concentriq has been grown, Proscia has found that a few key principles and priorities continue to guide both how the platform is built and how successful organisations adopt and expand their digital implementations. Here are a few of the most important features you should assess in a platform as you grow your digital pathology practice.